3,3-diphenylpropanenitrile

We are 3,3-diphenylpropanenitrile CAS:2286-54-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:3,3-diphenylpropanenitrile
CAS.NO:2286-54-6
Synonyms:3,3-diphenylpropanenitrile
2-Cyano-1,1-diphenylethane
3,3-diphenyl-propionitrile
Molecular Formula:C15H13N
Molecular Weight:207.27000
 
Physical and Chemical Properties:
Density:1.057
Melting point:86ºC
Boiling point:174ºC
Flash point:194.4ºC
Index of Refraction:1.574
 
Specification:
Appearance:White to off-white powder
Assay:≥98.0%
Moisture:≤0.2%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate

3,3-diphenylpropanenitrile


Related News: Catalent’s clinical supply network includes nine cGMP-certified clinical packaging facilities across North America, Europe and Asia, and more than 50 strategically-located depots around the world, providing local and regional options for clinical storage, distribution, expiry update and relabeling services, and clinical returns management.5-bromo-3 – [(1R) -1- (2,6-dicloro-3-fluorofenil) etoxi] piridin-2-amina CAS:877399-00-3 Trial results demonstrated that Oligomannate statistically improved cognitive function in mild-to-moderate AD patients as early as week 4 and the benefit was sustained at each follow-up assessment visit,” Shanghai Green Valley Pharmaceuticals, which developed the drug along with two academic institutions in China, said in a statement.1-fenil-1,2,3,4-tetrahidroisoquinolina CAS:22990-19-8 ICIG has agreed to offer employment to the unit’s approximately 120 employees upon closing, and plans to maintain operations at its primary location, a manufacturing facility in Liestal, Switzerland.675126-26-8 At the same time, through years of imitation and advanced technology learning, more and more domestic companies have participated in the field of highly original and characteristic APIs.The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.

Related Products
Product Name
(Z)-2-(2-Aminothiazole-4-yl-)-2-trityloxyimino acetic acid View Details
Isobutyryl chloride View Details
2,3-Dimethylbromobenzene View Details
3-Nitrophthalic anhydride manufacturer 4-Chloro-3-(trifluoromethyl)phenyl isocyanate manufacturer BOC-L-Proline manufacturer 4-Chloro-3-pyridinesulfonamide manufacturer Ethyl linoleate (JAN) manufacturer